Lupin Limited
LUPIN
주식 순위
#2107
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
주가
$21.49
시가총액
$9.83B
변동 (1일)
0.41%
변동 (1년)
-2.62%
국가
IN
거래 Lupin Limited (LUPIN)
카테고리
Healthcare
Lupin Limited (LUPIN)의 수익
Jun 2026 기준 수익 TTM: $824.86M
Lupin Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 $824.86M입니다. 2024년에 회사는 $290.50M의 수익을 올렸으며 이는 2023년의 수익 $87.18M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Lupin Limited의 수익 기록 (2004 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $824.86M | 75.71% |
| 2025 | $469.45M | 61.60% |
| 2024 | $290.50M | 233.20% |
| 2023 | $87.18M | -148.23% |
| 2022 | $-180.77M | -178.93% |
| 2021 | $229.01M | 127.84% |
| 2020 | $100.52M | -50.46% |
| 2019 | $202.90M | 141.60% |
| 2018 | $83.98M | -84.63% |
| 2017 | $546.37M | 8.74% |
| 2016 | $502.47M | -8.18% |
| 2015 | $547.26M | -3.94% |
| 2014 | $569.71M | 60.84% |
| 2013 | $354.21M | 50.17% |
| 2012 | $235.88M | 5.71% |
| 2011 | $223.13M | 19.92% |
| 2010 | $186.07M | 55.87% |
| 2009 | $119.38M | -11.57% |
| 2008 | $135.00M | 43.62% |
| 2007 | $93.99M | 85.65% |
| 2006 | $50.63M | 132.81% |
| 2005 | $21.75M | -50.60% |
| 2004 | $44.02M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 113.92% |
IN
|
